Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office
This article was originally published in The Tan Sheet
Executive Summary
NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26